已收录 268921 条政策
 政策提纲
  • 暂无提纲
Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV
[摘要] We describe a rare case of healing from low differentiated cholangiocarcinoma stage T4N1M0 with atypical genetic mutation in geneBRAFV600E for this tumor. A 38-year-old female patient was operated in National Surgery Institute due to cholangiocellular carcinoma (CCA) of left liver lobe with anterior abdominal wall invasion, invasion into diaphragm, pericardium. Left liver resection with lymphatic dissection, pericardial resection was performed. Adjuvant chemotherapy (GEMOX) didn’t give any results. Treatment with pembrolizumab also didn’t result in any improvement. Next generation sequencing molecular tumor profiling revealed mutation inBRAFV600E gene. Target therapy with dabrafenib and trametinib, aBRAFgene inhibitors was initiated and resulted in a full response. The patient is for 2 years tumor free with no signs of recurrence. To our knowledge our case report is longest in the world for stage IV CCA treated with dabrafenib + trametinib.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 肿瘤学
[关键词]  [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文